|
Study
|
Study design
|
Median age of the crizotinib group
|
Number of patients in the crizotinib group
|
Number of patients in the corresponding group (different treatment or no treatment)
|
Duration of treatment
|
Adverse effects of crizotinib (Grades 3–5)
|
|
Del Valle and Chang 2019 [14]
|
Retrospective cohort study
|
42
|
22
|
NA
|
|
Bradycardia
|
4.5%
|
|
Prolonged QTc
|
4.5%
|
|
Complete heart block
|
4.5%
|
|
Nausea, vomiting
|
4.5%
|
|
Transaminitis
|
4.5%
|
|
Pneumonitis
|
4.5%
|
|
Neutropenia
|
13.6%
|
|
Mohieldin et al. 2018 [15]
|
Retrospective cohort study
|
53
|
38
|
NA
|
4 years 8 months
|
Fatigue
|
2.6%
|
|
Peripheral edema
|
5.3%
|
|
Transaminitis
|
7.9%
|
|
Diarrhea
|
7.9%
|
|
Prolonged QT
|
7.9%
|
|
Kapoor et al. 2022 [16]
|
Retrospective cohort study
|
50
|
188
|
NA
|
49.4 months
|
Transaminitis
|
4.8%
|
|
QTc prolongation
|
4.2%
|
|
Liu et al. 2019 [17]
|
Retrospective cohort study
|
49.5
|
104
|
NA
|
4 years
|
Elevated transaminases
|
4.8%
|
|
Neutropenia
|
2.9%
|
|
Anemia
|
1%
|
|
Rosa et al. 2022 [18]
|
Observational prospective and retrospective cohort study
|
60.5
|
91
|
NA
|
2years 7 months
|
Elevated transaminase levels
|
4.4%
|
|
Infections and infestations
|
2.2%
|
|
Benign neoplasia
|
1.1%
|
|
Bradycardia
|
1.1%
|
|
Skin disorders
|
1.1%
|
|
Leukopenia
|
1.1%
|
|
Neutropenia
|
4.4%
|
|
Nervous system disorders
|
1.1%
|
|
Gastrointestinal disorders
|
4.4%
|
|
Visual disorders
|
1.1%
|
|
Renal and urinary disorders
|
1.1%
|
|
Respiratory disorders
|
2.2%
|
|
Ueno et al. 2019 [19]
|
Retrospective cohort study
|
61
|
2028
|
NA
|
52 weeks
|
Gastrointestinal disorders
|
8.8%
|
|
Eye disorders
|
0.6%
|
|
Hepatobiliary disorders
|
10.2%
|
|
Nervous system disorders
|
1.3%
|
|
Metabolism and nutrition disorders
|
4.7%
|
|
Respiratory, thoracic and mediastinal disorders
|
4.6%
|
|
Infections and infestations
|
4.6%
|
|
Skin and subcutaneous tissue disorders
|
0.4%
|
|
Blood and lymphatic system disorders
|
3.9%
|
|
Cardiac disorders
|
1%
|
|
Renal and urinary disorders
|
0.7%
|
|
Psychiatric disorders
|
0.5%
|
|
Vascular disorders
|
0.9%
|
|
Musculoskeletal and connective tissue disorders
|
0.2%
|
|
Neoplasms benign, malignant, and unspecified (including cysts and polyps)
|
1%
|
|
Endocrine disorders
|
0.1%
|
|
Congenital, familial, and hereditary disorders
|
0.1%
|
